The contralateral progression in a cohort of Chinese adult patients with unilateral moyamoya disease after revascularization: a single-center long-term retrospective study

Xiao Tian · Miao Hu · Jianjian Zhang

Received: 20 December 2021 / Accepted: 9 February 2022 / Published online: 26 March 2022
© The Author(s) 2022

Abstract

Background Moyamoya disease (MMD) is a chronic progressive cerebrovascular disease mainly existing in the Asian population, which can be divided into unilateral and bilateral types. Contralateral progression has been reported in pediatric patients with unilateral MMD, while large series about contralateral progression in Chinese adult patients were rare. The goal of this study is to elucidate the clinical features and incidence of contralateral progression in Chinese MMD adult patients.

Methods One hundred one Chinese adult patients with unilateral MMD who received surgery treatments between January 2015 and January 2017 in our hospital were enrolled in this study. This study contained 89 patients. Digital subtraction angiography was performed in all patients for initial diagnosis, and magnetic resonance angiography was repeated 6 months from the initial operation and then annually. Clinical characteristics, contralateral progression, and risk factors were studied. Previous related studies were also reviewed and meta-analyzed.

Results Of these 89 patients, contralateral progression was identified in 8 patients (9.0%) within a median follow-up period of 63 months, which was lower than that in previous studies (25.9%). Single-factor analysis and multivariate analysis did not reveal significant risk factors related to the contralateral progression.

Conclusion The progress rate in this cohort of Chinese adult patients with unilateral MMD after revascularization was 9.0%, which indicates that some of the unilateral MMD were an early form of bilateral MMD rather than a separate condition.

Trial registration. This work was approved by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University (approval number: Kelun-2017005).

Keywords Adult · Chinese · Moyamoya disease · Progression · Unilateral

Background

Moyamoya disease (MMD) is a chronic cerebrovascular occlusive disease that is characterized by developing stenosis or occlusion at the distal internal carotid artery (ICA) and/or the initial anterior cerebral artery (ACA) and middle cerebral artery (MCA), complemented with the formation of intensive moyamoya-like vessels [23]. The typical MMD was defined as moyamoya-specific angiographic changes in bilateral hemispheres [6]. However, MMD can be considered “unilateral” if typical MMD angiographic changes are observed on one side, while normal angiography on the contralateral side [15, 17]. The annual incidence of bilateral MMD and unilateral MMD is respectively 1.13/100,000 and 0.23/100,000 in Japan [7]. The age distribution of MMD is significantly bimodal, with a moderate peak in the first decade of life and a major peak at 35–45 years of age [3]. This brings about essential questions: Is adult MMD a continuum of pediatric MMD? Does unilateral MMD, which is more common in adults, progress to bilateral MMD [15]? Previous studies had mainly focused on the contralateral progression changes in pediatric MMD patients [20, 21].
while large series concerning the progression from adult unilateral MMD to bilateral lesions, especially in those with Chinese ethnic background, were rare [14, 16]. Up to now, there were only 14 clinical studies regarding the unilateral MMD processed to bilateral lesions [8, 9, 11–16, 18–21, 24, 26] (6 from South Korea, 6 from Japan, 1 from the USA, 1 from China). The sample size of unilateral MMD patients in all studies was relatively small (<70), except the latest two (>100) [18, 26].

The present study described the clinical features in a cohort of Chinese adult patients with unilateral MMD after revascularization from our hospital and tried to clarify the characteristics of contralateral progression in these patients.

Methods

Patient selection and data collection

This retrospective study included all consecutively treated adult (>18 years) individuals who visited our hospital between January 2015 and January 2017. The unilateral MMD was diagnosed via the digital subtraction angiography (DSA) in accordance with the following criteria: (1) stenosis/occlusion changes at the end of ICA or the proximal ACA or MCA on one cerebral hemisphere (which was identified as the original side); (2) moyamoya-like vascular networks in arterial areas near the occlusive or stenotic lesions; (3) absence of arterial stenosis or occlusion on the contralateral side; and (4) exclusion of conditions associated with moyamoya syndrome (MMS) such as intracranial atherosclerosis, systemic vasculitis, Down syndrome, acute stroke, hyperthyroidism, meningitis, neurofibromatosis, prior skull-base radiation therapy, leptomeningeal infection, or autoimmune disease. The angiographic stage was identified according to the Suzuki Grading System [23]. The single-photon emission computed tomography (SPECT) was adopted to check the perfusion status. The indication to surgery included patients with symptomatic MMD (ischemic or hemorrhagic) with apparent hemodynamic compromise [25].

At 6 months after the initial surgery, magnetic resonance angiography (MRA) was repeated and then repeated annually if the patient remained asymptomatic. The contralateral progression was defined as the detection of newly developed stenosis at the terminal ICA or the proximal ACA or MCA or posterior cerebral artery (PCA) with an MRA steno-occlusive change in the previously intact hemisphere during the follow-up period [26]. The DSA was performed to confirm before the contralateral revascularization. Atherosclerosis or other etiologies which can also cause intracranial vessel stenosis were excluded during the follow-up period.

One hundred one unilateral MMD adult patients were initially identified; all of them were treated with the standard superficial temporal artery (STA)-MCA bypass combined with encephalo-duro-myo-synangiosis (EDMS) revascularization by 2 surgeons (J.Z. or J.C.) on the original side according to the published procedures [25]. Among them, 10 patients were excluded for the lack of necessary follow-up information, and 2 patients were excluded for the follow-up duration of less than 36 months. Thus, 89 unilateral MMD patients were included in this study.

The baseline characteristics including age, sex, associated disease, and family history were collected from the electric medical record system. The onset of MMD was divided into 4 types: transient ischemic attack (TIA), ischemic (infarction, frequent TIA), hemorrhagic (intracerebral hemorrhage), and other (headache, motor dysfunction, etc.).

Search strategy and study identification

In order to analyze the development of contralateral MMD more comprehensively, a comprehensive search was performed to identify studies regarding the unilateral MMD processed to bilateral lesions. A literature search was performed in PubMed, Embase, and Ovid via all the possible combinations of “moyamoya disease,” “progres- sion,” “unilateral,” and “bilateral” up to March 20, 2020. We only included studies satisfied with the following criteria: (1) patients with MMD diagnosis confirmed by radiological and clinical criteria, (2) the sample size of unilateral MMD patients >5, (3) include the description of the contralateral progression, and (4) the necessary follow-up information is available. We excluded those studies without clearly distinguishing between MMD and MMS, as well as studies presented by languages other than English. References in identified articles were also manually screened.

Two reviewers independently reviewed full texts of all identified studies and independently extracted data from the included studies. Discrepancies between the two reviewers were resolved by discussion.

Statistical analysis

SPSS (version 26.0; SPSS Inc, Chicago, IL) was used for all statistical analyses. Data were reported as numbers (percentage) or medians (interquartile ranges, IQR). The Mann–Whitney U test was used to compare continuous variables that do not obey normal distribution, and categorical variables were compared using the chi-square test. Logistic regression analysis was used to detect risk factors related to contralateral progression. The contralateral progress rate
was transformed with the Freeman-Tukey variant of arc-
sine square prior to statistical pooling. For every analysis,
$P < 0.05$ was considered statistically significant.

Results

Clinical results

Among the 89 Chinese adult patients with unilateral
MMD (median age: 47 years, range: 31–54 years, 53
females [59.6%] and 36 males [40.6%]), original moy-
amoya-angiographic change was observed in 52 right
hemispheres (58.4%) and 37 left hemispheres (41.6%).

The angiographic Suzuki stages on the original side
were mainly III (41.6%) and IV (37.1%). Clinical
onsets: 34 cases were hemorrhagic (38.2%), 28 cases
were ischemic (31.5%), 22 cases were TIA, and 5 were
other symptoms (5.6%).

Contralateral progression

During the follow-up period, the contralateral progres-
sion was detected in 8 patients (representative case in
Fig. 1). The progress rate was 9.0% (8/89). Among them,
5 patients were female, and 3 were male. The progress-
ion occurred on 5 left hemispheres and 3 right hemi-
spheres. The detailed baseline demographics and medi-
cal profiles of these 8 patients are listed in Table 2. All
patients had received combined bypass surgery after
contralateral progression. No perioperative complica-
tion was detected.

We then divided all patients into “progression group”
(8 patients) and “non-progression group” (81 patients)
according to whether there was a contralateral progres-
sion. In order to determine if there was a significant dif-
ference between these two groups or any risk factor related to
the progression of the initial unaffected side, single-factor
analysis (Table 3) and multivariate analysis (Table 4)
were performed. However, no statically significant difference
was found in terms of age, sex, original side (including
hemisphere, stage, and onset), associated disease, family
history, or follow-up duration.

Discussion

Unilateral MMD had been considered “probable” MMD
to distinguish it from the “defined” bilateral MMD. To
avoid possible misunderstandings, the term “unilateral
MMD” had been proposed in the guideline for MMD in
2011 [17]. Same genetic defects such as the
\textit{RNF213} mutation might result in different phenotypes of unilateral or
bilateral MMD [2]. However, up to now, it is still not clear
whether there is a certain degree of difference in etiology
and natural history between the unilateral and the usual
bilateral MMD. Even so, the unilateral MMD might be
a suitable model to examine the pathogenetic process of
MMD, because the bilateral MMD exhibits complex and
ambiguous pathological findings that do not allow identi-
ﬁcation of cause versus effect [18]. In order to accurately
analyze the progression of the unilateral MMD, MMS was
excluded in our study because the MMS-associated dis-
eases such as sickle cell disease, Graves’ disease (GD),
and Down syndrome [1, 5] might have positive or negative
effects on the angiographic and symptomatic progression.

Table 1 Baseline characteristics of included cases with unilateral moyamoya disease

| Characteristic                              | All patients ($n = 89$) |
|--------------------------------------------|------------------------|
| Age (year) (medians (IQR))                 | 47 (31–54)             |
| Sex ($n$ (%))                              |                        |
| Female                                     | 53 (59.6)              |
| Male                                       | 36 (40.6)              |
| Original side ($n$ (%))                    |                        |
| Right                                      | 52 (58.4)              |
| Left                                       | 37 (41.6)              |
| Suzuki stage on the original side ($n$ (%))|                        |
| II                                         | 8 (9.0)                |
| III                                        | 37 (41.6)              |
| IV                                         | 33 (37.1)              |
| V                                          | 10 (11.2)              |
| VI                                         | 1 (1.1)                |
| Onset on the original side ($n$ (%))        |                        |
| Hemorrhagic                                | 34 (38.2)              |
| Ischemic                                   | 28 (31.5)              |
| TIA                                        | 22 (24.7)              |
| Other                                      | 5 (5.6)                |
| Associated disease ($n$ (%))                |                        |
| Hypertension                               | 12 (13.5)              |
| Aneurysm                                   | 6 (6.7)                |
| Diabetes                                   | 3 (3.4)                |
| Other                                      | 8 (9.0)                |
| Family history ($n$ (%))                    | 9 (10.1)               |
| Follow-up duration (months) (medians (IQR))| 63 (48-78)             |

Abbreviation: $IQR$ interquartile ranges, TIA transient ischemic attack
For example, Chen et al. [5] observed that the disease progression was more frequent in MMS patients with GD than that in patients without GD during the follow-up period, especially in unilateral disease.

Unilateral MMD was reported more common in females [7]. In our study, the female–male ratio was approximately 1.5:1, which was consistent with previous studies. Unilateral MMD was frequently reported to develop into bilateral lesions in pediatric patients [9]. The similar phenomenon was rarely reported in adult patients [8], and the progress rate of unilateral MMD to bilateral MMD was varied in previous studies. According to our literature review, 2 studies [15, 16] only focused on adult patients (progress rates were 17.8% and 36.4%, respectively), while 6 studies [9, 11, 20, 21, 24, 26] only focused on pediatric patients. The median progress rate in previous studies was 29.01% (ranges from 0 to 100%). In our study, all included samples were adult unilateral MMD patients. The progress rate was 9.0%, which was lower than previous reports. The reason might be due to the relatively short follow-up duration in our study. In previous studies, the contralateral progression could take 7 to 8 years after initial diagnosis [16]. Therefore, the period between primary diagnosis and disease progression was notably extended in some cases, and long-term follow-up would be crucial for the detection of the complete progression of unilateral MMD. The different definitions of “unilateral MMD” in various studies might also have an impact on the progression rate. For example, some researchers not only considered patients with normal angiographic findings of the contralateral hemisphere as “unilateral,” but also those with mild abnormalities in the contralateral ICA, MCA, or ACA [14, 22], while some others only included patients with a normal angiographic appearance in the contralateral side [24]. In the present study, patients who originally showed contralateral cerebrovascular stenosis on DSA, even very slight, were judged as bilateral MMD and excluded in the patient selection stage. Therefore, during the limited follow-up period, we might observe fewer progressive patients. In addition, the Chinese ethnic background might also contribute to the lower progress rate, since almost all previous studies were conducted within the Japanese or South Korean population who seem to have more excessive prevalence and incidence of MMD [25]. Indeed, the progress rate in a cohort of Chinese adults and pediatric MMD patients reported by Zhang et al. [26] in 2016 was also relatively lower (16.5%) than most studies.

Several studies have reported various risk factors regarding the contralateral progression, such as the age at diagnosis [24], the contralateral equivocal/mild angiographic stenosis change [14], and the familial history [20]. In our study, although we compared several parameters between the progression group and the non-progression group, no significant risk factor had been found. The lack of significance might be due to the small numbers analyzed, because statistical analysis for risk factors on progression in only 8 patients with progression lacks reference significance; however, other possible explanations are also suggested. On the one hand, there existed contradictory results regarding those reported risk factors among the previous studies. For example, Kelly et al. [14] observed that the initial contralateral ACA angiographic defect represented an indicator of contralateral progression, while Yeon et al. [24] reported no association between the visibility of the contralateral A1 segment and the contralateral progression. On the other hand, the mechanisms
of unilateral progression to bilateral MMD might involve genetic and structural complexity such as the dysregulation of endothelial remodeling and vascular cells [4], which need more professional detection methods to explore. Recently, Lee et al. [18] used the time-of-flight (TOF) sequence from brain magnetic resonance imaging (MRI) to measure the endothelial shear stress around the normally appearing terminal ICA and found that the endothelial shear stress was an independent indicator to predict the contralateral progression of unilateral MMD. Another factor, the degree of involvement of the posterior circulation, may also represent a possible “biomarker” for aggression of disease progression [10]. However, there was no posterior circulation involvement in our 8 patients with contralateral progression.

The exploration of how unilateral MMD develops to bilateral MMD could provide indirect but indispensable evidence to understand the MMD as an entirety and progressive diseases. Clinically, the identification of unilateral patients liable to develop bilateral disease also would be of considerable clinical benefit [24]. Understanding the expected process of progression, accompanied with the understanding of specialized risk factors related to the development of the contralateral lesions, would give neurosurgeons a more precise clue to design personalized follow-up strategies [26]. For the unaffected side, instead of prophylactic contralateral revascularization, careful and long-term follow-up was more necessary for the early detection of contralateral progression, so as to timely determine surgical revascularization. Early detection and prevention of ischemic or hemorrhagic stroke were crucial for improving the prognosis of patients.

The present study has limitations. First, as mentioned above, the follow-up duration in this study was relatively short. The mean follow-up period for the whole group was just over 5.25 years. Longer follow-up time might reveal more patients with progress. And in order to reduce the DSA radiation received by patients and the cost of reexamination, we used MRA as the way of reexamination after surgery. Although this is an acceptable way according to many published studies, we do agree that this approach may ignore subtle changes that would have been identified via routine DSA. This may explain our low incidence of progression. Second, since this is a retrospective analysis of a cohort of Chinese adults with unilateral MMD, the results were limited by selection bias. Third, we did not perform hemodynamic comparison in these two groups such as cerebral blood flow, oxygen extraction fraction, or cerebrovascular reserve, although which had not been found significantly associated with contralateral progression in previous studies. And we also did not perform additional tests such as $RNF213$ gene subtype or vessel wall MRI data, which may further explain potential mechanisms of the contralateral progression. Fourth, the patient population in this study was relatively small. Since the patients with unilateral MMD

| Table 2 Clinical characteristics of 8 cases with contralateral progression |
|-----------------------------------------------|
| Patient | Age (year) | Sex | Original side (Suzuki stage) | Follow-up duration (months) | Surgery on procession side | Procession side (Suzuki stage) | Symptom on procession side | Associated disease | Family history | Onset |
|---------|------------|-----|-----------------------------|-----------------------------|----------------------------|-----------------------------|---------------------------|------------------|--------------|-------|
| 1       | 31         | M   | L (3)                       | 54                          | Ischemic                   | R (3)                       | TIA                       | Hypertension     | No           | Ischemic |
| 2       | 47         | F   | L (4)                       | 56                          | TIA                        | R (2)                       | TIA                       |                 | Yes          | TIA     |
| 3       | 49         | F   | L (4)                       | 78                          | Ischemic                   | L (4)                       | TIA                       |                 |              | TIA     |
| 4       | 53         | M   | L (4)                       | 75                          | Ischemic                   | L (3)                       | TIA                       |                 | Yes          | Ischemic |
| 5       | 46         | F   | R (4)                       | 76                          | Hemorrhagic                | R (3)                       | TIA                       |                 | Yes          | Hemorrhagic |
| 6       | 39         | F   | L (3)                       | 62                          | Aneurysm                   | R (2)                       | TIA                       |                 | Yes          | Aneurysm |
| 7       | 38         | M   | L (2)                       | 64                          |                            |                            |                           |                 |              |         |
| 8       | 39         | F   | R (2)                       | 64                          |                            |                            |                           |                 |              |         |

| Patient | Sex | Follow-up duration (months) | Surgery on procession side | Procession side (Suzuki stage) | Symptom on procession side | Associated disease | Family history | Onset |
|---------|-----|----------------------------|-----------------------------|-----------------------------|---------------------------|------------------|--------------|-------|
| 1       | M   | 54                         | Ischemic                   | R (3)                       | TIA                       | Hypertension     | No           | Ischemic |
| 2       | F   | 56                         | TIA                        | R (2)                       | TIA                       |                 | Yes          | TIA     |
| 3       | F   | 78                         | Ischemic                   | L (4)                       | TIA                       |                 |              | TIA     |
| 4       | M   | 75                         | Ischemic                   | L (3)                       | TIA                       |                 | Yes          | Ischemic |
| 5       | F   | 76                         | Hemorrhagic                | R (3)                       | TIA                       |                 | Yes          | Hemorrhagic |
| 6       | F   | 62                         | Aneurysm                   | R (2)                       | TIA                       |                 | Yes          |         |
| 7       | M   | 64                         |                            |                            |                           |                 |              |         |
| 8       | F   | 64                         |                            |                            |                           |                 |              |         |
only account for roughly 17% in all MMD patients, it is really difficult to have much more qualified patients in one hospital, and this may also explain why previous studies regarding this topic almost had a relatively small patient population.

**Conclusion**

We found a 9.0% progression rate of unilateral MMD after revascularization develops to bilateral MMD in a cohort of Chinese adult MMD patients. Our results indicated that some of the unilateral MMD were early forms of bilateral MMD rather than a separate condition; therefore, neurosurgeons ought to notice this potential change during the postoperative follow-up period.

**Abbreviations**

MMD: Moyamoya disease; ICA: Internal carotid artery; ACA: Anterior cerebral artery; MCA: Middle cerebral artery; DSA: Digital subtraction angiography; MRA: Magnetic resonance angiography; MMS: Moyamoya syndrome; STA: Superficial temporal artery; EDMS: Encephalo-duro-myo-synangiosis; TIA: Transient ischemic attack; TOF: Time-of-flight; MRI: Magnetic resonance imaging

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00701-022-05153-6.

**Acknowledgements** The authors thank all participants in the study.
Author contribution CRediT taxonomy, formal analysis, investigation, writing (original draft preparation), and writing (review and editing): X.T. and M.H. English grammar and usage error correction: J.Z. Conceptualization and supervision: J.Z. The manuscript has been read and approved by all the authors.

Funding No Funding.

Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Ethical approval and informed consent The requirement for informed consent was waived since all information was anonymized before analysis. All methods were implemented according to relevant regulations and guidelines and approved by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University (approval number: Kelun-2017005).

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Alamri A, Hever P, Cheserem J et al (2019) Encephaloduroarterio-syndangiosis (EDAS) in the management of moyamoya syndrome in children with sickle cell disease. British journal of neurosurgery 33:161–164. https://doi.org/10.1080/02688697.2017.1339227
2. Bang OY, Chung JW, Kim DH, et al. (2019) Moyamoya disease and spectra of RNF213 vasculopathy. Translational stroke research https://doi.org/10.1007/s12975-019-00743-6.
3. Bao XY, Wang QN, Zhang Y et al (2019) Epidemiology of moyamoya disease in China: single-center, population-based study. World Neurosurg 122:e917–e923. https://doi.org/10.1016/j.wneu.2018.10.175
4. Chatzizisis YS, Coskun AU, Jonas M et al (2007) Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 49:2379–2393. https://doi.org/10.1016/j.jacc.2007.02.059
5. Chen JB, Lei D, He M et al (2015) Clinical features and disease progression in moyamoya disease patients with Graves disease. J Neurosurg 123:848–855. https://doi.org/10.1093/jnci/dju141140
6. Fukui M (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (‘moyamoya’ disease) Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare. Japan. Clinical neurology and neurosurgery 99(Suppl 2):S238-240
7. Hayashi K, Horie N, Izumo T et al (2014) A nationwide survey on unilateral moyamoya disease in Japan. Clinical neurology and neurosurgery 124:1–5. https://doi.org/10.1016/j.clineuro.2014.06.010
8. Hayashi K, Suyama K, Nagata I (2010) Clinical features of unilateral moyamoya disease. Neurol Med Chir (Tokyo) 50:378–385. https://doi.org/10.2176/nmc.50.378
9. Hirotsune N, Meguro T, Kawada S et al (1997) Long-term follow-up study of patients with unilateral moyamoya disease. Clinical neurology and neurosurgery 99(Suppl 2):S178–181. https://doi.org/10.1016/s0033-8467(97)00043-7
10. Hishikawa T, Tokunaga K, Sugiu K et al (2013) Assessment of the difference in posterior circulation involvement between pediatric and adult patients with moyamoya disease. J Neurosurg 119:961–965. https://doi.org/10.1093/jnci/djt113
11. Houkin K, Abe H, Yoshimoto T et al (1996) Is “unilateral” moyamoya disease different from moyamoya disease? J Neurosurg 85:772–776. https://doi.org/10.1093/jnci/965.5.0772
12. Joo SP, Kim TS, Lee IK et al (2011) A genome-wide study of moyamoya-type cerebrovascular disease in the Korean population. Journal of Korean Neurosurgical Society 50:486–491. https://doi.org/10.3340/jkns.2011.50.6.486
13. Kawano T, Fukui M, Hashimoto N et al (1994) Follow-up study of patients with “unilateral” moyamoya disease. Neurol Med Chir (Tokyo) 34:744–747. https://doi.org/10.2176/nmc.34.744
14. Kelly ME, Bell-Stephens TE, Marks MP et al (2006) Progression of unilateral moyamoya disease: a clinical series. Cerebrovasc Dis 22:109–115. https://doi.org/10.1159/000093238
15. Kim JE, Kim KM, Kim JG et al (2012) Clinical features of adult moyamoya disease with special reference to the diagnosis. Neurol Med Chir (Tokyo) 52:311–317. https://doi.org/10.2176/nmc.52.311
16. Kuroda S, Ishikawa T, Houkin K et al (2005) Incidence and clinical features of disease progression in adult moyamoya disease. Stroke 36:2148–2153. https://doi.org/10.1161/01.STR.0000182256.32489.99
17. Kuroda S, Houkin K (2008) Moyamoya disease: current concepts and future perspectives. Lancet Neurol 7:1056–1066. https://doi.org/10.1016/s1474-4422(08)70240-0
18. Lee WJ, Jeong SK, Han KS et al (2020) Impact of endothelial shear stress on the bilateral progression of unilateral moyamoya disease. Stroke 51:775–783. https://doi.org/10.1161/strokea.119.028117
19. Matsushima T, Inoue T, Natori Y et al (1994) Children with unilateral occlusion or stenosis of the ICA associated with surrounding moyamoya vessels—“unilateral” moyamoya disease. Acta Neurochir (Wien) 131:196–202. https://doi.org/10.1007/bf01808612
20. Park EK, Lee YH, Shim KW et al (2011) Natural history and progression factors of unilateral moyamoya disease in pediatric patients. Child’s nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 27:1281–1287. https://doi.org/10.1007/s00381-011-1469-y
21. Seol HJ, Wang KC, Kim SK et al (2006) Unilateral (probable) moyamoya disease: long-term follow-up of seven cases. Child’s nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 22:145–150. https://doi.org/10.1007/s00381-005-1234-1
22. Smith ER and Scott RM (2008) Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus 24: E17. https://doi.org/10.3171/foc.2008/24/2/e17.
23. Suzuki J, Takaku A (1969) Cerebrovascular, “moyamoya” disease Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20:288–299. https://doi.org/10.1001/archneur.1969.00480 09076012
24. Yeon JY, Shin HJ, Kong DS et al (2011) The prediction of contralateral progression in children and adolescents with unilateral moyamoya disease. Stroke 42:2973–2976. https://doi.org/10.1161/ strokea.111.622522
25. Zhang J, Li S, Fujimura M, et al. (2019) Hemodynamic analysis of the recipient parasympathetic cortical arteries for predicting postoperative
hyperperfusion during STA-MCA bypass in adult patients with moyamoya disease. J Neurosurg 1–8. https://doi.org/10.3171/2019.10.Jns191207.

26. Zhang Q, Wang R, Liu Y et al (2016) Clinical features and long-term outcomes of unilateral moyamoya disease. World Neurosurg 96:474–482. https://doi.org/10.1016/j.wneu.2016.09.018

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.